logo
Plus   Neg
Share
Email

Merck Says FDA Okays New Monotherapy Indication For KEYTRUDA

Merck & Co., Inc. (MRK) said Wednesday that the U.S. Food and Drug Administration approved KEYTRUDA, the company's anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

The company warned that Immune-mediated adverse reactions, which may be severe or fatal, can occur with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, severe skin reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Based on the severity of the adverse reaction, KEYTRUDA should be withheld or discontinued and corticosteroids administered if appropriate.

KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>